Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 6, 175-86

Development of Oral Agent in the Treatment of Multiple Sclerosis: How the First Available Oral Therapy, Fingolimod Will Change Therapeutic Paradigm Approach

Affiliations
Review

Development of Oral Agent in the Treatment of Multiple Sclerosis: How the First Available Oral Therapy, Fingolimod Will Change Therapeutic Paradigm Approach

Claudio Gasperini et al. Drug Des Devel Ther.

Abstract

Multiple sclerosis (MS) is a chronic inflammatory disorder of the central nervous system, traditionally considered to be an autoimmune, demyelinating disease. Based on this understanding, the initial therapeutic strategies were directed at immune modulation and inflammation control. At present, there are five licensed first-line disease-modifying drugs and two second-line treatments in MS. Currently available MS therapies have shown significant efficacy throughout many trials, but they produce different side-effect profiles in patients. Since they are well known and safe, they require regular and frequent parenteral administration and are associated with limited long-term treatment adherence. Thus, there is an important need for the development of new therapeutic strategies. Several oral compounds are in late-stage development for treating MS. Fingolimod (FTY720; Novartis, Basel, Switzerland) is an oral sphingosine-1-phosphase receptor modulator which has demonstrated superior efficacy compared with placebo and interferon β-1a in Phase III studies and has been approved in the treatment of MS. We summarily review the oral compounds in study, focusing on the recent development, approval and the clinical experience with FTY720.

Keywords: fingolimod; fty720; multiple sclerosis; oral compounds; patient satisfaction; phosphate; sphingosine 1.

Similar articles

See all similar articles

Cited by 9 PubMed Central articles

See all "Cited by" articles

References

    1. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain. 1989;112(Pt 1):133–146. - PubMed
    1. Murray TJ. Diagnosis and treatment of multiple sclerosis. BMJ. 2006;332:525–527. - PMC - PubMed
    1. Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372:1502–1517. - PubMed
    1. Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain. 2006;129:606–616. - PubMed
    1. Lassmann H, Bruck W, Lucchinetti CF. The immunopathology of multiple sclerosis: an overview. Brain Pathol. 2007;17:210–218. - PubMed

MeSH terms

Feedback